anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition of matter includes a cationic dye and a solvent, wherein the composition does not have particles that are greater than 25 microns in diameter. The disclosure also describes a method for producing a composition of matter. An ink jet cartridge includes the composition of matter. A device includes a substrate having an image printed thereon with the composition of matter. A method includes using an inkjet printer to print a graphic on a first major surface of a substrate; moistening a user's skin surface; contacting the first major surface of the substrate to the user's moistened skin surface; and removing the substrate from the user's skin surface, thereby leaving a mirror image of the printed graphic on the user's skin surface. Moreover, an art kit includes a first substrate having a graphic printed thereon and a second substrate having a mirror image of the graphic printed thereon.
Methods and systems are disclosed for covariate prediction from methylation features. A system identifies a feature set of genomic regions by training one or more regressions to evaluate a covariance score of a genomic region. The system may select the feature set with the highest indicativeness scores and may consider other selection criteria. The system trains an age prediction model using training samples with reported chronological age label(s). The system can further utilize the chronological age prediction to predict a likelihood of cancer in a test sample. To do so, the system may compare the predicted covariate value and/or label to the reported value and/or label. In one embodiment, the system may utilize an age residual threshold to determine whether there is a strong likelihood of presence of cancer. In other embodiments, the system may utilize the predicted chronological age value as a feature to a cancer classifier.
OBJECTIVE: Given the scarcity of studies analyzing the clinical predictors of pediatric septic cases that would progress to septic shock, this study aimed to determine strong predictors for pediatric emergency department (PED) patients with sepsis at risk for septic shock and mortality.
METHODS: We conducted chart reviews of patients with ≥ 2 age-adjusted quick Sequential Organ Failure Assessment score (qSOFA) criteria to recognize patients with an infectious disease in two tertiary PEDs between January 1, 2021, and April 30, 2022. The age range of included patients was 1 month to 18 years. The primary outcome was development of septic shock within 48 h of PED attendance. The secondary outcome was sepsis-related 28-day mortality. Initial important variables in the PED and hemodynamics with the highest and lowest values during the first 24 h of admission were also analyzed.
RESULTS: Overall, 417 patients were admitted because of sepsis and met the eligibility criteria for the study. Forty-nine cases progressed to septic shock within 48 h after admission and 368 were discharged without progression. General demographics, laboratory data, and hemodynamics were analyzed by multivariate analysis. Only the minimum diastolic blood pressure/systolic blood pressure ratio (D/S ratio) during the first 24 h after admission remained as an independent predictor of progression to septic shock and 28-day mortality. The best cutoff values of the D/S ratio for predicting septic shock and 28-day mortality were 0.52 and 0.47, respectively.
CONCLUSIONS: The D/S ratio is a practical bedside scoring system in the PED and had good discriminative ability in predicting the progression of septic shock and in-hospital mortality in PED patients. Further validation is essential in other settings.
Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
Disorders in the regulatory arm of the adaptive immune system result in autoimmune-mediated diseases. While systemic immunosuppression is the prevailing approach to manage them, it fails to achieve long-lasting remission due to concomitant suppression of the regulatory arm and carries the risk of heightened susceptibility to infections and malignancies. Alopecia areata is a condition characterized by localized hair loss due to autoimmunity. The accessibility of the skin allows local rather than systemic intervention to avoid broad immunosuppression. It is hypothesized that the expansion of endogenous regulatory T cells (Tregs) at the site of antigen encounter can restore the immune balance and generate a long-lasting tolerogenic response. A hydrogel microneedle (MN) patch is therefore utilized for delivery of CCL22, a Treg-chemoattractant, and IL-2, a Treg survival factor to amplify them. In an immune-mediated murine model of alopecia, local bolstering of Treg numbers is shown, leading to sustained hair regrowth and attenuation of inflammatory pathways. In a humanized skin transplant mouse model, expansion of Tregs within human skin is confirmed without engendering peripheral immunosuppression. The patch offers high-loading capacity and shelf-life stability for prospective clinical translation. By harmonizing immune responses locally, the aim is to reshape the landscape of autoimmune skin disease management.
The stevia-sweetened beverage contains 30.1 mg of steviol equivalents. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
A cosmetic composition for the temporary reshaping of keratinic fibres comprising 1-10 wt% film former, 3-15 wt% wax, 0.5-12 wt% cosmetic oil, 5-12 wt% a branched or unbranched hydrocarbon, 1-4 wt% of an emulsifier and 30-50 wt% water. The composition is for temporarily reshaping hair, particularly rigid hair e.g. beard hair. The composition may be suitable as a “2 in 1” product for use on both scalp and beard hair. Preferably, the film former is a nonionic copolymer, most preferably vinylpyrrolidone/vinyl acetate copolymer. The wax may be a mixture of waxes such as a fatty acid ester and a fatty acid, for example synthetic beeswax and Copernicia Cerifera (carnauba) wax. The branched or unbranched hydrocarbon is preferably a mixture of paraffins and olefins, most preferably petrolatum. The cosmetic oil may be a monoester of carboxylic acids comprising 8 carbon atoms or less with fatty alcohols, or a synthetic cosmetic oil, dimethicone is exemplified. Preferably the emulsifier is a nonionic surfactant. The composition may further comprise a hydrophobically modified (meth)acrylic acid copolymer. Also disclosed is a method for the temporary reshaping of keratinic fibres comprising applying to the keratinic fibres the cosmetic composition and reshaping or fixing the keratinic fibres.
The screening of antigen-specific B cells has been pivotal for biotherapeutic development for over four decades. Conventional antibody discovery strategies, including hybridoma technology and single B cell screening, remain widely used based on their simplicity, accessibility, and proven track record. Technological advances and the urgent demand for infectious disease applications have shifted paradigms in single B cell screening, resulting in increased throughput and decreased time and labor, ultimately enabling the rapid identification of monoclonal antibodies with desired biological and biophysical properties. Herein, we provide an overview of conventional and emergent single B cell screening approaches and highlight their potential strengths and weaknesses. We also detail the impact of innovative technologies-including miniaturization, microfluidics, multiplexing, and deep sequencing-on the recent identification of broadly neutralizing antibodies for infectious disease applications. Overall, the coronavirus disease 2019 (COVID-19) pandemic has reinvigorated efforts to improve the efficiency of monoclonal antibody discovery, resulting in the broad application of innovative antibody discovery methodologies for treating a myriad of infectious diseases and pathological conditions.
FIELD: medicine, therapy. SUBSTANCE: method involves bowels rinsing with 2 l 0.5% solution of sodium hydrocarbonate at 38-42 C for 2 days followed by rinsing with 0.15% solution of sodium thiosulfate for 2 days and then bowels is rinsed for 2 weeks with solutions of anti-inflammatory, cardiotonic, diuretic and cholagogue herbs (6 times at temperature of solutions 38-40 C). Tubage is carried out at breaks between bowels rinsing. Method ensures to recovery homeostasis effectively and improve disintoxicating function of liver that results to decrease of arterial pressure. EFFECT: enhanced effectiveness of method. 2 ex
PROBLEM TO BE SOLVED: To obtain an enhancing agent for the suppression of an antibody producing cell useful for the treatment and prevention of autoimmune diseases and a composition containing the same and an antibody producing cell suppressant. SOLUTION: This enhancing agent for the suppression of an antibody producing cell contains an essence of a plant belonging to the genus Kochia of family Chenopodiaceae. Preferably the fruit of the plant (e.g. Kochia separis) as it is, a processed material such as pickled with salt, dried, crushed or sliced or an extract obtained by extracting the processed material, are used. As a daily dosage, 100-10000mg for an adult divided to several portions a day, is preferably administered orally. As the antibody producing cell suppressant, an essence of a basidiomycete of family Polyporaceae such as Ganoderma lucidum is preferable, and it has a suppressing effect on the antibody producing action of the antibody producing cells and reduces the amount of the antibody production.  The composition contains the antibody producing cell suppressant and the enhancing agent for the antibody producing cell suppressant in a ratio of (99:1)-(8:2), and can be prepared as a medicinal composition, a food composition, an agent for external use for the skin, a cosmetic material, etc. A daily dosage is 1-100g as the medicinal composition and 1-500g as the food composition for an adult.
The invention relates to a non-invasive imaging method of bacteria. One embodiment comprises labeling the bacteria with a radioisotope, then delivering it to the gut of a human or animal. Another embodiment is to label bacteriophages, then administer them to a human or animal, so that they infect (and thus co-localize with) bacteria already resident in the human or animal. The bacteriophage can then be imaged, showing the location of the resident bacteria of interest. In another embodiment, the invention is related more generally to the labelling of bacteria or bacteriophages with a radio-metal or radioisotope to render the labeled gut bacteria and the bacteria in the body visible to nuclear medicine PET and SPECT imaging guided by functional/structural MRI and/or CT imaging. In another embodiment, the invention is related more generally to the labelling of bacteria or bacteriophages (both or just one) with a radio-metal or radioisotope to render the gut bacteria and the bacteria in the body visible to nuclear medicine PET and SPECT imaging guided by functional/structural MRI and/or CT imaging or visible by MRI alone or in combination with either PET or SPECT.
The utility model provides a skin recovery film for medical use, and a main body is a transparent thin film for medical use. One side of the thin film is coated with the medical adhesive which is covered with the release paper; the other side of the thin film is also covered with the release paper. The intermediate part of the release paper is a rectangular frame which is formed after the release paper is ripped away. The utility model is characterized in that the middle of the long frame of the rectangular frame is provided with an indentation which does not communicate with the external periphery; the short end of the other side of the release paper is provided with an indentation which is communicated with the external periphery. The utility model changes the previous indentation which communicates with the external periphery on the middle of the long frame of the rectangular frame into the non-communicating indentation, so as to enhance the anchorage force of the release paper to the thin film. When the skin recovery film for medical use is used, the release paper covered on the adhesive is ripped away along the indentation; the thin film has sufficient anchorage force, so the thin film does not easily bend and bond together. Therefore, the operation is convenient, the material is saved and the cost is reduced because only one short end of the other side of the release paper is provided with the indentation which communicates with the external periphery.
This study aims to utilize large-scale real-time imaging data from multiple centers, including the First Affiliated Hospital of Zhejiang University, Lishui Central Hospital, and the Second Affiliated Hospital of Nanchang University, within a prospective real-world cohort. Radiologists will be stratified by years of experience and randomly assigned into two groups. One group will use the pancreatic cancer screening model, PANDA PLUS, while the other will use a pseudo-PANDA model to assist in diagnosis during routine clinical practice. Both groups will be tracked for cases with imaging reports suggesting possible PDAC positivity, and follow-up will verify the final outcomes of patients with negative imaging reports. Patients with positive reports will receive regular follow-up every three months to obtain clinical history, pathological gold standards, initial tumor markers, resectability classification, TNM staging, and long-term survival data. The study will evaluate the effectiveness of PANDA PLUS in assisting clinical radiologists in diagnosing PDAC under non-contrast CT conditions and compare the sensitivity, specificity, and positive predictive value of PDAC detection between the pseudo-PANDA and PANDA PLUS models. Additionally, it will compare differences in initial TNM staging, resectability rates, and long-term survival data. The study will also assess the detection efficiency of PANDA PLUS for triple-negative PDAC (negative clinical symptoms, negative tumor markers, and negative non-contrast CT imaging).
This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories, as well as the geographic size. These differences can lead to variable and unequal access to effective therapies for GvHD. This document will provide comprehensive and practical guidance that can be applied across Canada by healthcare professionals caring for patients with cGvHD. Hopefully, this guideline, based on input from GvHD treaters across the country, will aid in standardizing cGvHD care and facilitate access to much-needed novel therapies. This consensus paper aims to discuss the optimal approach to the initial assessment of cGvHD, review the severity scoring and global grading system, discuss systemic and topical treatments, as well as supportive therapies, and propose a therapeutic algorithm for frontline and subsequent lines of cGvHD treatment in adults and pediatric patients. Finally, we will make suggestions about the future direction of cGvHD treatment development such as (1) a mode-of-action-based cGvHD drug selection, according to the pathogenesis of cGvHD, (2) a combination strategy with the introduction of newer targeted drugs, (3) a steroid-free regimen, particularly for front line therapy for cGvHD treatment, and (4) a pre-emptive approach which can prevent the progression of cGvHD in high-risk patients destined to develop severe and highly morbid forms of cGvHD.
POTS patients will be current patients of the study practitioners within the autonomic, cardiology PM\&R clinics and autonomic laboratory. This cohort may receive a codified treatment plan within the following 7 treatment categories which are also standard of care procedures based on clinical recommendations: (1) salt, fluid and diet management; (2) exercise program with or without PT; (3) cognitive behavioral therapy or other counseling; (4) vagal stimulation forms like yoga, breathing exercises, relaxation, microauricular stimulation; (5) pharmacotherapy for pressure maintenance; (6) medications for pain and headache; (7) medications for the gastrointestinal issues.
Patients with lung adenocarcinoma were treated with Trilaciclib (240mg/m2, d1, within 4 hours before each chemotherapy) combined with pemetrexed and carboplatin (dose according to the guideline recommendation, d1, Q3W). "For squamous lung cancer, Trilaciclib (d1, 240mg/m2, 4 hours before each chemotherapy) plus paclitaxel/albumin-bound paclitaxel plus carboplatin (dose according to guideline recommendation, d1), Q3W." In the second cycle, patients were left to their own discretion with or without treaclib combination therapy.
Duodenal ulcer (DU) is the most common gastroscopic manifestation of abdominal Henoch-Schönlein purpura (HSP), which may cause severe bleeding and often requires esophagogastroduodenoscopy (EGD) to confirm the diagnosis. However, the condition of children with HSP changes rapidly; not all children are able to undergo EGD on time, and some hospitals do not have a pediatric EGD unit. Therefore, assessing the risk factors for developing DU in HSP using simple and readily available indicators is essential. Children with HSP at Wuhan Children Hospital from June 2020 to June 2022 were included in the training set and completed EGD. The patients were divided into 2 groups: those with (DU group) and without DU (non-DU group). Data were collected from the 2 groups, and univariate and multivariate logistic regression analyses were used to compare the 2 groups. Children with HSP admitted between July 2022 and June 2023 were included in the validation set. Four indicators, prognostic nutrition index, albumin (ALB), gastrointestinal (GI) bleeding, and duration of onset before EGD, were found in the DU and non-DU groups. GI bleeding and prognostic nutritional index (PNI) ≤ 53.0 have strong predictability for patients with HSP and DU. GI bleeding and PNI ≤ 53.0 may provide new reference evidence for condition assessment and treatment.
Background: Various coping strategies have been shown to alleviate the negative effects of trauma, yet the significance of prosocial behaviour in this realm has been notably underexplored. The present study explored the hypothesis that engaging in prosocial behaviour mitigates the impacts of trauma by promoting a sense of competence and relatedness, post-traumatic growth (PTG), and reconstruction of meaning.Methods: Three consecutive studies were conducted with college students to compare differences in consequence of prosocial behaviours between a trauma group and a control group. Study 1 (N = 96) used self-reported experiences of traumatic vs non-traumatic events; Study 2 (N = 43) used exposure vs. no exposure to video of an earthquake; Study 3 (N = 20) used a randomized controlled trial (RCT) of a prosocial-themed intervention vs. no intervention. Outcomes in all studies were assessed by self-report questionnaires.Results: Trauma damaged participants' sense of competence and meaningfulness. Prosocial behaviour relieved the impact of trauma on meaning, specifically manifested in the individuals' sense of meaningfulness and their search for meaning. Group interventions with a prosocial theme (based on effect size results) reduced post-traumatic stress disorder (PTSD) and enhanced PTG in victims. The promoting effect on PTG persisted a month later, and its enhancing effect on meaning manifested with a delay.Conclusion: Prosocial behaviour can potentially serve as a beneficial strategy for individuals coping with trauma because it helps enhance meaning and promotes PTG in victims. This conclusion is supported by laboratory experiments and a tentative small-scale intervention study, which provide an innovative perspective for future trauma interventions.
The study will consist of a clinical component and a scientific component consisting of laboratory investigations of potentially useful biochemical (lipid and protein) markers. Up to 50 SLS patients of all ages, gender and ethnic origins will be enrolled. A detailed clinical evaluation will be performed to determine the presence and extent of disease involving the skin, nervous system and eyes. Clinical testing will include brain magnetic resonance imaging (MRI) and spectroscopy (MRS), electroencephalography (EEG), neurocognitive tests, ophthalmologic examination with retinal photographs and optical coherence tomography (OCT), photographs of the skin and tests of cutaneous transepidermal water loss. Laboratory investigations will include lipid analyses (e.g. fatty alcohols, farnesol, fatty acids, ether glycerolipids, etc.) of blood, skin and urine; proteomic analysis of skin (stratum corneum); and measurements of leukocyte fatty alcohol and farnesol oxidation. A skin biopsy (optional) will be obtained for electron microscopy, measurement of lanthanum perfusion (transepidermal water loss), and/or establishing keratinocyte cultures. Correlations between clinical abnormalities and laboratory measurements will be tested to identify the most useful biomarkers for future diagnostic and therapeutic studies. To characterize the progression of phenotypic features over time, patients \<6 years of age will be followed yearly and patients ≥6 years of age will be followed every 3 years. In addition, a SLS patient registry will be established as a resource for future investigations in SLS.
FIRDAPSE can cause seizures. Seizures have been observed in patients without a history of seizures taking FIRDAPSE at the recommended doses, at various times after initiation of treatment, at an incidence of approximately 2%. Many of the patients were taking medications or had comorbid medical conditions that may have lowered the seizure threshold [see Drug Interactions (7.1)]. Seizures may be dose-dependent. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.